Consistently, tumor explants derived from colon cancers sensitive to GSI PF-03084014 showed higher levels of Notch1 and Wnt/β-catenin signaling components compared with the resistant samples and GSI treatment, affecting the activation of both pathways [177]. This evidence concerns the gene NOTCH1 and malignant colon neoplasm.